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Abstract HIV-1 infection cannot be cured because the virus persists as integrated proviral DNA
in long-lived cells despite years of suppressive antiretroviral therapy (ART). In a previous paper
(Zanini et al, 2015) we documented HIV-1 evolution in 10 untreated patients. Here we characterize
establishment, turnover, and evolution of viral DNA reservoirs in the same patients after 3–18 years
of suppressive ART. A median of 14% (range 0–42%) of the DNA sequences were defective due to
G-to-A hypermutation. Remaining DNA sequences showed no evidence of evolution over years of
suppressive ART. Most sequences from the DNA reservoirs were very similar to viruses actively
replicating in plasma (RNA sequences) shortly before start of ART. The results do not support
persistent HIV-1 replication as a mechanism to maintain the HIV-1 reservoir during suppressive
therapy. Rather, the data indicate that DNA variants are turning over as long as patients are
untreated and that suppressive ART halts this turnover.
DOI: 10.7554/eLife.18889.001
Introduction
Combination antiretroviral therapy (ART) has had significant effects on the morbidity and mortality
associated with human immunodeficiency virus type 1 (HIV-1) infection. ART very effectively sup-
presses active virus replication, but it cannot eradicate the infection because HIV-1 persists as inte-
grated proviral DNA in long-lived cells that constitute a virus reservoir. Latently infected resting
memory CD4+ T-lymphocytes (memory CD4 cells) represent the most solidly documented HIV-1 res-
ervoir (Eriksson et al., 2013; Chun et al., 1997, 1995). Fully functional integrated HIV-1 proviruses
are present in a small fraction of memory CD4 cells. These cells do not produce virus when they are
in a resting state, but can be induced to produce virus upon activation in vitro and in vivo
(Eriksson et al., 2013; Chun et al., 1995, 1997; Massanella and Richman, 2016). The activation
state of the infected cell and the viral encoded Tat feedback loop jointly determine latency and virus
production (Razooky et al., 2015; Rouzine et al., 2015).
Because of their importance to development of a cure for HIV-1 infection, many methods to
quantify HIV-1 reservoirs have been developed. The quantitative virus outgrowth assay (QVOA) has
been the ‘gold standard’ (von Stockenstrom et al., 2015; Massanella and Richman, 2016;
Bruner et al., 2015), but recent studies have revealed that this assay greatly underestimates the
true size of the functional reservoir (Ho et al., 2013; Bruner et al., 2016). In contrast, PCR-based
assays overestimate the size of the functional reservoir because they cannot distinguish between rep-
lication-competent and defective viral genomes (von Stockenstrom et al., 2015; Massanella and
Richman, 2016; Bruner et al., 2015, 2016). Many defective proviruses contain large internal
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deletions (Ho et al., 2013; Sanchez et al., 1997). Defective proviruses also result from APOBEC
editing, which induces G-to-A hypermutation (Yu et al., 2004; Kieffer et al., 2005; Stopak et al.,
2003; Bruner et al., 2016).
The HIV-1 reservoir is established early during primary infection and is remarkably quantitatively
and qualitatively stable. Siliciano et al. (2003) found a 44-month half-life for latently infected cells
capable of producing replication-competent virus in the QVOA. Similarly, HIV-1 DNA levels and
genetic compositions are very stable in patients receiving long-term suppressive ART
(von Stockenstrom et al., 2015; Besson et al., 2014; Josefsson et al., 2013; Kearney et al., 2014;
Gu¨nthard et al., 1999; Evering et al., 2012; Kieffer et al., 2004). Early ART reduces the reservoir’s
size and genetic complexity (Chomont et al., 2009; Josefsson et al., 2013; Lori et al., 1999;
Strain et al., 2005). Most studies suggest that the HIV-1 reservoir is maintained by the physiological
homeostasis of memory CD4 cells that in part involves occasional expansion and contraction of indi-
vidual CD4 cell clones (von Stockenstrom et al., 2015; Chomont et al., 2011, 2009). However, the
results of some studies have suggested that persistent virus replication may be an important contrib-
utor to the maintenance of the HIV-1 reservoir (Buzo´n et al., 2010; Yukl et al., 2010). Recently, Lor-
enzo-Redondo et al. (2016) reported evidence of rapid HIV-1 evolution in lymphoid tissue
reservoirs.
Despite their significance for HIV-1 cure efforts, relatively little is known about the pre-ART estab-
lishment and turnover of the HIV-1 reservoir. In this study, we characterized the establishment and
maintenance of the HIV-1 DNA reservoirs in 10 patients. We previously studied the evolution of HIV-
1 in these patients before ART by whole genome deep-sequencing of HIV-1 RNA in longitudinal
plasma samples (Zanini et al., 2015). We now sequenced HIV-1 DNA from peripheral blood mono-
nuclear cells (PBMCs) from these patients after many years of suppressive ART and compared these
reservoir DNA sequences with the replicating HIV populations that were present before ART. The
collection dates of all available samples relative to start of treatment are presented in Figure 1.
We found that the HIV-1 DNA populations remained genetically stable for up to 18 years after
the start of suppressive ART. The absence of genetic changes indicates that viral evolution and repli-
cation are not important mechanisms for the maintenance of HIV-1 reservoirs during supressive ART.
We also found that the variants that were replicating shortly before start of ART were overrepre-
sented in the HIV-1 DNA reservoirs. This excess of late variants in the DNA reservoirs indicated that
proviral HIV-1 variants continued to turn over with a half-life of approximately one year until the
patients began therapy. ART effectively froze the composition of the HIV-1 DNA reservoir in the
state it had at start of therapy.
-15y -10y -5y 0y 5y 10y 15y
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Figure 1. Sampling times before and after start of suppressive antiretroviral therapy. For each study participant, the thick grey bar indicates the period
of untreated HIV-1 replication. Circles indicate the collection times of the plasma samples used for whole genome deep sequencing of the HIV-1 RNA
populations (Zanini et al., 2015). Triangles and squares indicate the collection times of the PBMC samples used for p17gag deep sequencing of the
HIV-1 DNA populations. All times are relative to start of therapy.
DOI: 10.7554/eLife.18889.002
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Results
Patients and samples
The study population consisted of 10 HIV-1 infected patients who were diagnosed in Sweden
between 1990 and 2003. The following criteria were used to select the patients: (1) A relatively well-
defined time of infection; (2) Being treatment-naive for 5 years; and (3) Receiving suppressive ART
(plasma HIV-1 RNA levels continuously <50 copies/ml) for 2 years. We previously characterized
HIV-1 RNA populations in longitudinal plasma samples (6–12 per patients over 5–8 years). Results
for 9 out of the 10 patients were reported in Zanini et al. (2015). The tenth patient (p7) was part of
the previous study, but was not included in the final analyses of that study because the sequencing
of plasma samples obtained during the first years after infection had failed. The results for the
patient characteristics are presented in Figure 1 and Table 1.
For this study, we obtained sequence data from the HIV-1 DNA in viral reservoirs using deep
sequencing of the p17gag region of the HIV-1 genome in DNA prepared from PBMCs. Longitudinal
PBMC samples (1–3 samples per patient for up to a 2.6-year period) were obtained 3–18 years after
the start of suppressive ART (Figure 1 and Table 1). We defined viral DNA reservoirs as HIV-1
p17gag sequences that were still present in PBMCs after at least 2 years of suppressive ART. HIV-1
DNA template numbers were quantified by limiting dilution by the same p17gag PCR that was used
for sequencing. Identical p17gag sequences were merged into haplotypes while preserving their
abundance. Minor haplotypes were merged with major haplotypes if they differed by one mutation
(see Materials and methods section). Processed sequence data are available at hiv.tuebingen.mpg.
de. Raw sequencing reads from all HIV-1 DNA samples were deposited in the European Nucleotide
archive (study accession number PRJEB13841; sample accession numbers ERS1138001-
ERS1138025).
Proviral DNA sequences reflect pretreatment RNA sequences
The HIV-1 DNA sequences recapitulate the diversity observed in RNA sequences before treatment,
often with exact sequence matches, Figure 2 and Figure 2—figure supplement 1. While we
observed large variations in the abundance of haplotypes with sequence read frequencies varying
between 0.1 and 50% (Figure 2—figure supplement 2), the high similarities between RNA and
DNA sequences confirmed that our characterization of proviral diversity was specific and sensitive.
Variation in haplotype abundance likely reflects clonal expansion (Josefsson et al., 2013;
von Stockenstrom et al., 2015), independent integration of identical sequences, and resampling of
Table 1. Summary of patient characteristics.
Patient Gender Transmission Subtype Age* HIV RNA from plasma HIV DNA from PBMCs
# samples
First/last since
EDI† Time on ART† # templates
p1 F HET 01_AE 37 12 0.3 8.2 7.9/9.9/10.4 820/148/38
p2 M MSM B 32 6 0.2 5.5 6.9 75
p3 M MSM B 52 10 0.4 8.4 4.6/6.7/7.2 243/102/108
p5 M MSM B 38 7 0.4 5.9 4.0/6.3 180/72
p6 M HET C 31 7 0.2 7.0 3.0/5.0/5.5 115/15/nd
p7 M MSM B 31 11 6.3‡ 16.1 6.3/8.4/8.8 88/279/108
p8 M MSM B 35 7 0.2 6.0 8.4/10.6/10.9 180/55/175
p9 M MSM B 32 8 0.3 8.1 7.7/9.7/10.2 60/72/72
p10 M MSM B 34 9 0.1 6.2 16.2/18.3/18.6 249/116/51
p11 M MSM B 53 7 0.6 5.6 6.4/8.4/8.8 124/120/123
*at diagnosis;
†EDI: estimated date of infection; all times are given in years;
‡sequencing failed in earlier samples due to low plasma HIV-1 RNA levels.
DOI: 10.7554/eLife.18889.003
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the same original DNA templates during sequencing. However, the specific contributions of these
distinct mechanisms were difficult to determine in our sequencing results.
The estimated numbers of HIV DNA templates, the numbers of distinct haplotypes observed, and
the fractions of haplotypes present in multiple samples are presented in Supplementary file 1. If a
haplotype was present at a frequency >1%, it was also present in another sample from the same
patient in approximately one-third (median 0.29) of all cases.
Hypermutated sequences are frequent in HIV-1 reservoirs
We found that substantial proportions (median 14%; range 0–42%) of the p17gag DNA sequences
from the viral reservoirs were hypermutated and were therefore expected to be replication incompe-
tent (Figure 2—figure supplement 3). This result was consistent with the results of earlier research,
which showed that 9–30% of sequences were hypermutated (Josefsson et al., 2013; Bruner et al.,
2015; Kieffer et al., 2005). A small proportion of sequences had stop codons that were not obvi-
ously due to G-to-A hypermutation (mean 3%, range 0–12%). A proportion of sequences without
Figure 2. Reconstructed phylogenetic trees of plasma HIV-1 RNA sequences (circles) and PBMC HIV-1 DNA (triangles and squares) from two patients.
The RNA sequences were obtained from plasma samples collected before the start of suppressive antiretroviral therapy (ART). DNA sequences 1, 2,
and 3 were obtained from PBMCs collected after many years of suppressive ART (see Figure 1). The symbol colors indicate the sample date relative to
the start of therapy and use the same color scale as in Figure 1. The symbol size indicates the fraction of reads represented by the node. The trees
were built using the FastTree software (see Materials and methods section) (Price et al., 2010). Analogous phylogenetic trees for the remaining eight
study patients are presented in Figure 2—figure supplement 1.
DOI: 10.7554/eLife.18889.004
The following figure supplements are available for figure 2:
Figure supplement 1. Phylogenetic trees of plasma HIV-1 RNA and PBMC HIV-1 DNA sequences from all patients included in the study.
DOI: 10.7554/eLife.18889.005
Figure supplement 2. Distributions of frequencies of haplotypes.
DOI: 10.7554/eLife.18889.006
Figure supplement 3. Distributions of mutations in reads classified as hypermutanted or as non-hypermutated.
DOI: 10.7554/eLife.18889.007
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overt inactivating mutations were likely also replication incompetent due to mutations or deletions
outside of p17gag (Ho et al., 2013; Bruner et al., 2016). We excluded hypermutated sequences
from the main analyses, but we also performed complementary analyses that included hypermutated
sequences.
Lack of evidence of persistent replication in HIV-1 DNA reservoirs
Whether or not HIV-1 reservoirs are maintained by persistent replication remains controversial
(von Stockenstrom et al., 2015; Chomont et al., 2011, 2009; Buzo´n et al., 2010; Yukl et al.,
2010; Lorenzo-Redondo et al., 2016; Evering et al., 2012). We used the p17gag DNA sequences
from viral reservoirs to search for evidence of sequence evolution, which should occur if the virus
was replicating. Root-to-tip distances for plasma RNA populations and PBMC DNA populations
were calculated relative to the major RNA haplotype present in the first plasma sample.
Figure 3 presents the results for temporal changes in root-to-tip distances in HIV-1 RNA and
DNA populations obtained before and after the start of suppressive ART, respectively. Plasma HIV-1
RNA populations obtained before the start of ART evolved at a relatively constant rate
(Zanini et al., 2015); there was a steady increase in mean root-to-tip distances over time in Figure 3.
In sharp contrast, the HIV-1 DNA populations obtained after 3–18 years of suppressive therapy had
stable root-to-tip distances. Hypermutated DNA sequences had larger root-to-tip distances, but
these distances were also stable over time (Figure 3—figure supplement 1). To rule out biases due
to clonal expansion or PCR resampling, or both, we repeated this analyses while counting each
unique sequence only once; we obtained essentially the same results (Figure 3—figure
supplement 2).
The results for the rates of evolution before and after the start of suppressive ART are presented
in Table 2. In all 10 patients we found statistically significant evolution of plasma RNA sequences
before the start of therapy, with rates 1 4  10 3/year. In contrast, DNA sequences showed no sig-
nal of statistically significant evolution in DNA reservoirs during suppressive ART.
Taken together, our results did not indicate that persistent HIV-1 replication acts as a mechanism
to maintain the HIV-1 reservoir during suppressive therapy.
Time of deposition of reservoir HIV-1 DNA sequences
The phylogenetic analyses indicated that most of the HIV-1 DNA variants present in the PBMCs
matched the HIV-1 RNA variants detected in the plasma samples obtained shortly before the start of
therapy (Figure 2 and Figure 2—figure supplement 1). However, the phylogenetic trees also
revealed that DNA variants that matched the earliest plasma variants were present in some patients.
To investigate when the PBMC HIV-1 DNA variants were deposited in the viral reservoirs, we
compared the on-treatment PBMC DNA sequences with the longitudinal pre-treatment plasma RNA
sequences. For each p17gag DNA sequence, we determined the pre-treatment plasma sample and
the RNA haplotype that was the most likely source. This method assigned most of the HIV-1 DNA
sequences to the plasma samples closest to the start of treatment (Figure 4, panel A and Figure 4—
figure supplement 1). A combined analysis of the data for all patients (Figure 4, panel C) indicated
that approximately 60% of the DNA reads were most similar to RNA variants that were present in
plasma samples obtained during the last year before the start of therapy. The representation of the
variants present in the earlier plasma samples decreased; the half-life was 0.75 years going backward
in time from the start of therapy. Analyses in which each unique sequence was counted only once
revealed very similar results, which indicated that the findings were robust to possible sampling
biases from clonal expansions or PCR resampling, or both (Figure 4—figure supplement 2).
Sequences that matched sequences at earlier plasma sampling time points were found as minor
variants among the p17gag DNA sequences (Figure 4, panel B). Among these minor variants, the
DNA sequences matching plasma variants obtained within six months post-infection were overrepre-
sented in some patients (14%, 2.4%, 42%, <1%, and 6.9% of all the reads in patients 2, 3, 6, 8, and
11, respectively). On average approximately 5% of the reads matched plasma variants from the first
6 months after the estimated date of infection (EDI) (Figure 4, panel B). If the outlying data for
patient six were omitted, this fraction was 2%. Even 2% was unexpectedly high given the rapid DNA
decay during untreated HIV-1 infection. If the rates of seeding into the reservoirs were stable over
time, we would have expected a mean value of 0.14% (range < 0.001–0.32% across patients) of the
Brodin et al. eLife 2016;5:e18889. DOI: 10.7554/eLife.18889 5 of 15
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DNA sequences to match the earliest plasma variants. This result suggested that massive seeding of
HIV DNA into the viral reservoirs occurred during the first weeks and months post-infection.
In summary, viral variants that replicated shortly before the start of suppressive ART were over-
represented in the HIV-1 DNA reservoirs. This result indicated that the infected cells were turning
over (approximately one-year half-life) for as long as the patients were untreated. Suppressive ART
halted this turnover.
Figure 3. Root-to-tip distances. The plasma HIV-1 RNA sequences evolved steadily before the start of antiretroviral therapy (ART), while no evidence of
evolution was found in the PBMC HIV-1 DNA sequences obtained after the start of ART. For each patient, we have samples obtained before or at the
start of therapy (HIV-1 RNA from plasma), and samples obtained after the start of therapy (HIV-1 DNA from PBMCs). The error bars indicate ± one
standard deviation of the root-to-tip distances. The figure contains data on DNA sequences not classified as hypermutants. The analogous figures for
the hypermutants and haplotypes are presented in Figure 3—figure supplements 1 and 2, respectively.
DOI: 10.7554/eLife.18889.008
The following figure supplements are available for figure 3:
Figure supplement 1. Mean root-to-tip distances for plasma HIV-1 RNA sequences obtained before the start of ART and PBMC HIV-1 DNA sequences
obtained after the start of ART.
DOI: 10.7554/eLife.18889.009
Figure supplement 2. Mean root-to-tip distances for plasma HIV-1 RNA sequences obtained before the start of antiretroviral therapy (ART) and PBMC
HIV-1 DNA sequences obtained after the start of ART.
DOI: 10.7554/eLife.18889.010
Figure supplement 3. Short lived cells can generate a false signal of evolution.
DOI: 10.7554/eLife.18889.011
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Discussion
We investigated the composition and turnover of HIV-1 DNA sequences in viral reservoirs in patients
receiving long-term suppressive therapy. The reservoir HIV-1 DNA populations were remarkably sta-
ble and showed no evidence of active replication during ART. Since we had previously characterized
the HIV-1 populations in these patients prior to ART, we could determined how sequences in the
HIV-1 reservoir related to pre-treatment populations. In particular, we were able to show that
sequences in HIV-1 DNA reservoirs mainly derived from the populations present during the last year
before the start of suppressive therapy.
Our results indicate that persistent HIV-1 replication is not a mechanism for maintenance of HIV-1
reservoirs during suppressive therapy (Figure 3 and Table 2). This conclusion differs from the results
of a recent report by Lorenzo-Redondo et al. (2016) and of a few earlier reports (Yukl et al., 2010;
Buzo´n et al., 2010). However, our results are consistent with the results of other earlier studies
(von Stockenstrom et al., 2015; Besson et al., 2014; Josefsson et al., 2013; Kearney et al., 2014;
Gu¨nthard et al., 1999; Evering et al., 2012; Kieffer et al., 2004). Lorenzo-Redondo et al. (2016)
compared genetic diversity in HIV-1 RNA in plasma samples at the start of therapy with HIV-1 DNA
sequences obtained from blood and tissues at baseline, 3 months, and 6 months after the start of
treatment. The authors reported very high rates of evolution (7.4 12  10 3 changes per site per
year); these rates are approximately 3- to 5-fold greater than those typically observed in gag and
pol of replicating RNA populations. Such rapid evolution is incompatible with the lack of observable
changes in the reservoir sequences over the 20 times longer time intervals reported here (Figure 3—
figure supplement 2).
Without longitudinal data on the evolution of HIV-1 populations prior to treatment, the nature of
the changes reported by Lorenzo-Redondo et al. (2016) are difficult to determine. It is possible
that the reported temporal signal arises from changes in DNA reservoir composition during the first
6 months of therapy when short-lived cells infected with recently replicating virus variants gradually
disappear. Death of short-lived cells increases the proportions of longer-lived cells that sample fur-
ther back into the history of the infection. This scenario (Figure 3—figure supplement 3) would
result in sequence changes that do not indicate (forward) evolution. Instead these changes can cre-
ate an impression of ‘backward’ evolution towards older HIV variants due the preferential pruning of
later variants.
Lorenzo-Redondo et al. (2016) investigated HIV-1 DNA sequences in tissue and PBMC samples,
but we only examined PBMC samples. However, Lorenzo-Redondo et al. found similar rates in
PBMC compared to tissue samples. Furthermore, tissue and blood HIV-1 DNA variants should be
well-mixed during the time period that we investigated (Josefsson et al., 2013; von Stockenstrom
et al., 2015; Lorenzo-Redondo et al., 2016).
Table 2. Rates of evolution in plasma HIV-1 RNA and PBMC HIV-1 DNA sequences obtained before
the start and after the start of suppressive antiretroviral therapy, respectively.
Patient RNA rate DNA rate
[Year 1] p-value [Year 1] p-value
p1 4.4  10 3 <10 6  6  10 4 0.22
p2 3.7  10 3 <10 2  8  10 4 –
p3 4.1  10 3 <10 6  2  10 4 0.39
p5 4.8  10 3 <10 3 4  10 4 0.45
p6 1.4  10 3 <10 3  9  10 4 0.22
p7 1.3  10 3 <10 2  7  10 4 0.14
p8 2.9  10 3 <10 5 8  10 5 0.22
p9 2.6  10 3 <10 4 1  10 4 0.12
p10 3.6  10 3 <10 5  1  10 4 0.20
p11 1.2  10 3 <10 2 2  10 4 0.16
DOI: 10.7554/eLife.18889.012
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AB C
p1 p8
Figure 4. Probable origin of sequences in the DNA reservoir. For each HIV-1 DNA read obtained from the PBMCs, we determined the pre-treatment
plasma sample and HIV-1 RNA variant that was the most likely origin of the read. Panel A presents the results for the distribution of these pre-treatment
assignments for HIV-1 DNA reads from the three PBMC samples (DNA 1, 2, and 3) of patients p1 and p8 (compare trees in Figure 2). The analogous
graphs for all patients are presented in Figure 4—figure supplement 1. A large fraction of the reservoir DNA sequences was most closely related to
Figure 4 continued on next page
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Both Lorenzo-Redondo et al. (2016) and we studied DNA sequences in HIV-1 reservoirs, which
contain high proportions of defective virus (Ho et al., 2013; Bruner et al., 2016). The absence of
provirus evolution or turnover does not fully exclude the possibility that there was replication and
evolution of replication-competent viruses present in the reservoirs. However, if such replication
occurred, it involved a minority of infected cells and occurred below the detection limit of the deep-
sequencing method. To enrich for replication-competent and putatively evolving virus, QVOA fol-
lowed by sequencing of virus released into the supernatant should be performed, not sequencing
the total HIV-1 DNA (as done by Lorenzo-Redondo et al. [2016], us, and others [Josefsson et al.,
2013; Kieffer et al., 2005; Evering et al., 2012]). Our finding of genetic stability in the DNA reser-
voirs is consistent with Josefsson et al. (2013) and von Stockenstrom et al. (2015). They found
that defective HIV-1 DNA integrants present during long-term effective ART appear to be main-
tained by proliferation and longevity of infected cells and not by ongoing viral replication.
We had detailed longitudinal data on the evolution of the plasma HIV-1 RNA population from the
time of infection to the start of suppressive ART. Therefore, we could determine the time at which
the viruses in the DNA reservoirs had been deposited (Figure 4 and supplements). We found that a
majority of the variants present in the HIV-1 DNA reservoirs were derived from HIV-1 RNA variants
that had replicated during the last year before the start of suppressive ART. In contrast,
Frenkel et al. (2003) reported the persistence of greater numbers of earlier versus more recent virus
variants in a few children receiving suppressive ART. We found a similar, but much less prominent,
presence of variants replicating during the first 6 months post-infection (Figure 4, panel B). These
early variants were overrepresented relative to the expected level if deposition had been uniform
over time. This overrepresentation could be due to the high viral load present during primary HIV-1
infection and is consistent with results by Bruner et al. (2016), who found that defective proviruses
rapidly accumulate during acute HIV-1 infection. However, we observed such an excess of early var-
iants in only 5 out 10 patients.
Defective HIV-1 proviruses are unique in vivo labels of individual memory CD4 cell clones. Similar
to the sequencing of T-cell receptors, these labels can be used to track the fates of the memory
CD4 cells (Robins, 2013). This strategy was used by Imamichi et al. (2014), who found that a T-cell
clone carrying a defective HIV-1 provirus can persist for >17 years. Similarly, prenatally formed T-cell
receptors shared by twins have lifetimes that are >30 years (Pogorelyy et al., 2016). Our results are
consistent with such long T-cell life times once HIV replication is suppressed by ART. In untreated
infection, however, we estimate much faster turnover of infected cells with a half-life of approxi-
mately one year. This conclusion is based on the observation that most HIV-1 DNA sequences derive
from replicating virus shortly before the start of ART. The results of earlier studies, which were based
on different types of CD4 cell labelling, have indicated that CD4 cell die at a 3- to 4-fold increased
rate in untreated HIV-1-infected patients, compared with uninfected individuals and with patients
receiving suppressive ART (Hellerstein et al., 1999; McCune et al., 2000; Ribeiro et al., 2002). The
more dramatic difference that we observed might be due to that earlier studies estimated lifespans
of individual cells, whereas we estimated the lifespans of CD4 cell clones carrying defective provi-
ruses (i.e., infected cells and their daughter cells).
Figure 4 continued
the RNA sequences present in the plasma samples obtained during the last year before the start of therapy. Panels B and C present summaries of the
results for the distributions of the likely origins of the reservoir reads for all samples as a function of time since estimated date of infection (EDI) and
time before treatment start, respectively. The distribution of reads decays with the time from treatment start (half-life of approximately 0.75 years)
(Panel C). A small fraction of reads was estimated to originate from plasma samples obtained shortly post-infection (Panel B). We found these early
reservoir sequences in 50% of the patients.
DOI: 10.7554/eLife.18889.013
The following figure supplements are available for figure 4:
Figure supplement 1. The distribution of plausible seeding times of reservoir HIV-1 DNA sequences for all 10 patients.
DOI: 10.7554/eLife.18889.014
Figure supplement 2. Same as Figure 4—figure supplement 1, but counting each sequence once instead of weighted by the number of reads it
represents.
DOI: 10.7554/eLife.18889.015
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Our study had several limitations. We did not sort cells and therefore could not investigate
whether there were differences in HIV-1 turnover rates between different types and subsets of cells
(e.g., memory CD4 cells and their subsets). However, it is reasonable to assume that most of our
HIV-1 DNA sequences were from memory CD4+ T-lymphocytes because others have found that
these cells are the main HIV-1 reservoir (Eriksson et al., 2013; Chun et al., 1997, 1995). Because
we sequenced a relatively short region of the HIV-1 genome, we could not reliably distinguish
between replication-competent and defective viruses. We did not find evidence of evolution in pro-
viral DNA sequences, but we cannot rule out the possibility that a small subset of viruses was repli-
cating and remained undetected among the many defective viruses. However, our analyses of the
composition and turnover of the virus reservoir were aided by the fact that most of the viruses were
defective because these proviruses acted as inert in vivo labels of CD4 cell clones. We observed
large variations in the abundance of sequence haplotypes that likely indicate the presence of clonal
expansions (Josefsson et al., 2013; von Stockenstrom et al., 2015), independent integrations of
identical sequences, and resampling of the same original DNA templates during sequencing. Given
our sequencing method, we could not determine the relative contributions of these mechanisms.
We are using Primer ID sequencing (Jabara et al., 2011) to better understand the in vivo dynamics
of different viral haplotypes. Analysis of HIV integration sites represents an alternative method of
clonal expansion identification (Maldarelli et al., 2014; Cohn et al., 2015). However, such analysis
was not possible for us because we did not sequence the extreme ends of the LTRs. We analyzed
p17gag because it was part of our plasma HIV RNA dataset and because it has sufficient genetic
diversity to allow for accurate and valid comparisons between plasma RNA and PBMC DNA HIV
populations. Results from several analyses suggested that clonal expansion did not affect our results
in a qualitative manner. Clonal expansion would have resulted in artefactual over-representation of
some sequences. To control for this, we repeated the analyses in Figures 3 and 4 and counted each
haplotype only once. We obtained very similar results (Figure 3—figure supplement 2 and Fig-
ure 4—figure supplement 2). Consistent with our results and interpretation, Cohn et al. (2015)
found only a limited decrease in single integrations following the start of ART (from approximately
70 to 50%).
In summary, we found compelling evidence against persistent viral replication as a mechanism to
maintain the latent HIV-1 DNA reservoir during suppressive therapy. We also found that most of the
latently infected cells present during long-term suppressive ART were infected shortly before the
start of ART, and that T-cell turnover slowed down dramatically when ART began.
Materials and methods
Ethical statement
The study was performed according to Declaration of Helsinki requirements. Ethical approval was
granted by the Regional Ethical Review Board, Stockholm, Sweden (Dnr 2012/505 and 2014/646).
Written and oral informed consent was obtained from each patient that participated in the study.
Patients
The study population consisted of 10 HIV-1-infected patients who were diagnosed in Sweden
between 1990 and 2003. These patients had been included in a recent study of the population geno-
mics of intrapatient HIV-1 evolution (Zanini et al., 2015). The patients were selected based on the
following inclusion criteria: (1) A relatively well-defined time of infection (based on a negative HIV
antibody test <2 years before a first positive test or a laboratory-documented primary HIV infection);
(2) No ART during a minimum period of approximately 5 years after diagnosis; (3) Availability of bio-
bank plasma samples covering this time period; and (4) Later initiation of successful ART (plasma
viral levels <50 copies/ml) for 2 years. As previously described, 6–12 plasma samples per patient
were retrieved from biobanks and used for full-genome HIV-1 RNA sequencing (Zanini et al., 2015).
The same patient nomenclature was used in both studies. For this study, the same 10 patients were
asked to donate 70 ml fresh EDTA-treated blood on up to three occasions during a 2.5-year period.
These blood samples were obtained 3–18 years after the start of successful ART. The clinical and lab-
oratory findings (including Fiebig staging and BED testing) were used to calculate the EDI, as
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previously described (Zanini et al., 2015). The results for the characteristics of the patients and the
samples are presented in Table 1.
HIV-1 RNA sequencing from plasma
Whole-genome deep-sequencing of the virus RNA populations present in the plasma samples
obtained before the start of therapy was performed as previously described (Zanini et al., 2015).
Briefly, the total plasma RNA was extracted using an RNeasy Lipid Tissue Mini Kit (Qiagen Cat No.
74804). The extracted RNA was amplified using a one-step RT-PCR, outer primers for six overlap-
ping regions, and Superscript III One-Step RT-PCR with Platinum Taq High Fidelity High Enzyme Mix
(Invitrogen, Carlsbad, California, US). An optimized Illumina Nextera XT library preparation protocol
and a kit from the same supplier were used to build the DNA libraries, which were sequenced using
an Illumina MiSeq instrument and 2  250 bp or 2  300 bp sequencing kits (MS-102–2003/MS-10–
3003). For the present study, a section of the p17gag region of the HIV-1 genome was extracted
from the full-genome RNA data set. A median number of 146 (inter-quartile range 56–400) high
quality reads was obtained. The cDNA template numbers are available in Zanini et al. (2015).
HIV-1 DNA sequencing from PBMCs
A total of approximately 70 ml fresh whole blood was split between seven Vacutainer (EDTA) tubes.
The PMBCs were isolated using Ficoll-Paque PLUS (GE Healthcare Bio-Sciences AB, Uppsala, Swe-
den) centrifugation according to the manufacturer’s instructions. Total DNA was extracted from the
PBMCs using the OMEGA E.Z.N.A Blood DNA Mini Kit (Omega Bio-Tek, Norcross, Georgia) or the
QIAamp DNA Blood Mini Kit (Qiagen GmbH, Hilden, Germany) according to the manufacturer’s
instructions. The amount of DNA was measured using a Qubit dsDNA HS Assay Kit (Invitrogen,
Eugene, Oregon, USA). Patient-specific nested primers (Integrated DNA Technologies) were used to
amplify a 387 bp long portion of the p17gag gene corresponding to positions 787 to 1173 in the
HxB2 reference sequence. The primers were designed based on the plasma RNA sequences from
each patient (Supplementary file 2). Outer primers and Platinum Taq DNA Polymerase High Fidelity
(Invitrogen, Carlsbad, California, US) were used for the first PCR. The protocol began with a denatur-
ation step at 94˚C for 2 min followed by 15 PCR cycles of denaturation at 94˚C for 20 s, annealing at
50˚C for 20 s, extension at 72˚C for 30 s, and a final extension step at 72˚C for 6 min. For the second
PCR, 2.5 ml of the product from the first PCR was amplified using inner primers and the cycle profile
and enzyme as for the first PCR. Amplified DNA was purified using Agencourt AMPure XP (Beckman
Coulter, Beverly, Massachusetts) and quantified using Qubit. For each sample, the number of HIV-1
DNA templates used for sequencing was roughly quantified in triplicate by limiting dilution using the
same PCR conditions, three dilutions (usually 0.5 mg, 0.1 mg, 0.02 mg DNA), and Poisson statistics.
The plasmids NL4-3 and SF162 were used for control experiments, which were performed to evalu-
ate PCR-induced recombination. Equal proportions of the plasmids were spiked into human DNA
and were amplified using the same PCR conditions as previously described. The results revealed that
there was minimal PCR-induced recombination in this short amplicon.
Sequencing and read processing
The HIV-specific primers were flanked by NexteraXT adapters. To construct sequencing libraries,
indices and sequencing primers were added in 12–15 cycles of additional PCR. The amplicons were
sequenced using an Illumina MiSeq instrument and 2  250 cycle kits. A total of 6500 to 190,000
(median 35,000) paired-end reads were generated per sample. The overlapping paired-end
sequencing reads were merged to create synthetic reads spanning the entire p17gag amplicon. The
nucleotide on the read with the higher quality score was used for the cases of disagreement
between paired reads. We counted the numbers of times a particular p17gag sequence was
observed, and performed subsequent analysis using read-abundance pairs. To reduce the effects of
sequencing and PCR errors, we combined rare sequences (below frequency 0.002) with common
sequences if they differed at no more than one position. Specifically, starting with the rarest sequen-
ces, we merged rare sequences with the most common sequence that was one base away. The cut-
off value of 0.002 is the typical error frequency of the pipeline (Zanini et al., 2015). Less than 1 in
1000 reads that began with the HIV specific primer sequence could not be assigned with confidence
to the previously determined RNA sequences. Most of these reads mapped to the human genome.
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All analyses were performed using Python and the libraries NumPy, BioPython, and Matplotlib
(Cock et al., 2009; van der Walt et al., 2011; Hunter, 2007). All read files have been uploaded to
ENA with study accession number PRJEB13841.
Hypermutation detection
To classify sequences into hypermutated and non-hypermutated sequences, we counted mutations
at positions that did not vary in the RNA samples obtained before therapy. If greater than four muta-
tions were observed, and at least one-half of them were GfiA, the sequence was considered to be a
hypermutant. The results for the distributions of the different transition mutations relative to the
closest genome found in the RNA samples are presented in Figure 2—figure supplement 3 for
reads classified as hypermutants, or not. The results we obtained for sequences classified as non-
hypermutants were very similar to the results obtained when only using sequences without stop
codons.
Phylogenetic analysis
We reconstructed phylogenetic trees using the approximate maximum likelihood method imple-
mented in the FastTree software (Price et al., 2010). The tips were annotated with frequency,
source, and sample date using custom-made Python scripts.
Statistical analysis
The root-to-tip distances were calculated as the mean distance between a sample and the founder
sequence, approximated by the consensus sequence of the first RNA sample. This root-to-tip dis-
tance was regressed against time to determine the rate of evolution in the absence of treatment.
The root-to-tip sequence of the last RNA sample and the DNA samples was regressed against time
to determine the rate of evolution on treatment. To determine the most likely seeding time for a
PBMC p17gag DNA sequence, we calculated the likelihood of sampling this sequence given the
SNP frequencies in each plasma RNA sample and assigned the sequence to the sample that had the
greatest likelihood value.
Scripts used for processing and analysis of the data as well as plotting the results are available at
https://github.com/neherlab/HIVEVO_reservoir.
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